Susanne Geistlich

Cholecystokinin 2 Receptor Agonist ¹⁷⁷Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

Christof Rottenburger, Guillaume Nicolas, Lisa McDougall et al. · Journal of Nuclear Medicine · 2019 · 88 citations · Full text

Medicine, Nuclear Medicine, Pharmacology +16

Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog¹⁷⁷Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?

Alexander Sauter, Rosalba Mansi, Ulrich Hassiepen et al. · Journal of Nuclear Medicine · 2018 · 59 citations · Full text

Medicine, Oncology, Pharmacology +16

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

Julia Fricke, Frida Westerbergh, Lisa McDougall et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2024 · 40 citations · Full text

Medicine, Oncology, Pharmacology +16

A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5

Geoffrey Warnock, Michael Sommerauer, Linjing Mu et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 25 citations · Full text

Medicine, Neuroscience, Nuclear Medicine +16

¹⁶¹Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of¹⁶¹Tb into the Clinic

Chiara Favaretto, Pascal V. Grundler, Zeynep Talip et al. · Journal of Nuclear Medicine · 2023 · 13 citations · Full text

Medicine, Nuclear Medicine, Oncology +17